Glaxo stops antidepressant research: patient improvement can’t be measured w/ blood tests only subjective mood surveys
GlaxoSmithKline PLC said it will stop research into new antidepressants and focus on diseases for which it believes it can develop more valuable drugs, a major shift for a company that developed some of the biggest-selling antidepressants of the past 20 years.